FDA Inspection
Boiron Inc.Boiron Inc. – FDA Inspection, Jun 26, 2026
Record Details
This FDA Inspection record concerns Boiron Inc., with an inspection on June 26, 2026, issued by the Philadelphia District Office, covering human drugs.
View Company Profile
ID · ae45dc26-27c6-46bd-afac-9e2480c2c93f
Inspection Facts
- Inspection number
- 1324326
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
2- 21 CFR 211.22(d)Procedures not in writing, fully followed
- 21 CFR 211.25(a)Training--operations, GMPs, written procedures
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Boiron Inc.
3| Date | Classification | Office | Project area |
|---|---|---|---|
| October 25, 2021 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| February 14, 2017 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| March 18, 2011 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Boiron Inc.
- FDA Inspection 1155509 - 2021-10-25
- FDA Inspection 1007059 - 2017-02-14
- FDA Inspection 716890 - 2011-03-18
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.